NSE · CIPLA
Cipla Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹5,078 Cr with net profit ₹862 Cr — a 16.98% net margin, versus 13.36% the period before.
Shareholding
As of 2026-06-30
- Promoter29.21%
- Public15.95%
- FII20.21%
- DII34.63%
5,78,679 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.44× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #3 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.34 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd.(this company) | ₹1,10,943 Cr | 31 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.83 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.51 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.67 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.48 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
AI analysis
AI-generated · google/gemini-2.5-flashCipla Ltd. has a market capitalization of Rs 116459 Cr. The company reported revenue of Rs 29044.6 Cr with a profit margin of 14% and a P/E ratio of 209.84. Earnings per share (EPS) stood at 47.12. The 52-week high for the share price was 1673 and the 52-week low was 1165.7.
Positives
- +Revenue grew 2.2% to Rs 29044.6 Cr.
- +Debt-to-equity ratio is low at 0.02.
- +Promoter shareholding is not pledged, standing at 0%.
Negatives
- −The P/E ratio of 209.84 is high relative to the EPS of 47.12.
- −Promoter holding of 29.2143% is less than 30% for the period ending March 31, 2026.
- −Quarterly revenue for Mar 2026 was Rs 6541.2 Cr, a decrease from Dec 2025's Rs 7074.48 Cr.
- −Quarterly net profit for Mar 2026 was Rs 554.64 Cr, lower than Dec 2025's Rs 675.8 Cr.
Financial Performance
Cipla Ltd. reported a revenue of Rs 29044.6 Cr, which represents a growth of 2.2%. The company's net profit margin was 14%. Earnings per share for the latest period stood at 47.12. The EBITDA for the annual period ending March 2026 was Rs 5553.93 Cr.
Profitability & Returns
The company's Return on Equity (ROE) was 11.27% and Return on Capital Employed (ROCE) was 14.94%. The profit margin for the reported period was 14%. The P/E ratio stood at 209.84, which is significantly higher than its EPS of 47.12. The dividend yield was 90%.
Balance Sheet
Cipla Ltd. maintains a low debt-to-equity ratio of 0.02, indicating minimal reliance on borrowed funds. The book value per share is Rs 426.22. No promoter shares are reported as pledged, indicating strong promoter commitment.
Ownership & Pledges
As of March 31, 2026, promoter holding in Cipla Ltd. was 29.2143%. Domestic Institutional Investors (DII) held 31.9693% and Foreign Institutional Investors (FII) held 22.557% of the company's shares. Public shareholding was 16.2594%, with total institutional holding at 54.5263%. There are no promoter pledged shares reported.
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.